The migraineurs experienced significant relief in dry eye symptoms and photophobia with the administration of Botulinum toxin A (BoNT-A), independent of baseline tear film volume, as per the findings of a retrospective analysis published in the British Journal of Opthalmology.

A total of 76 migraineurs from a Miami Veterans Affairs Medical Center Neurotoxin Clinic who obtained BoNT-A from 23 August 2017 to13 December 2017 were selected for the analysis. A chart review was introduced to identify the demographic data and all comorbidities. The symptoms before and after administrating BoNT-A injection were assessed using the standardised, validated surveys. The phenol red thread (PRT) test was used to evaluate the preinjection tear volumes.

A significant association was seen in the scores of Photophobia, dry eye symptom and preinjection migraine and none of these was linked with preinjection PRT effects. Also after the administration of BoNT-A, the Photophobia, dry eye symptoms and preinjection migraine scores showed a significant association with no connection with preinjection PRT outcomes. Photophobia scores increased notably after the BoNT-A administration, whereas the dry eye symptoms improved significantly only in those patients showed severe manifestations at baseline. Subjects with severe dry eye symptoms exhibited more improvements were observed during the logistic regression analysis of all people with dry eye symptoms (DEQ-5 ≥6). The inference behind these improvements may be the modulation of shared trigeminal neural pathways.